Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease

International Journal of Cardiology

Volumn 126, Issue 2, 2008, Pages 247-251

  Monami, Matteo ^a   Marchionni, Niccolò ^a   Masotti, Giulio ^a   Mannucci, Edoardo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Biguanides; Diabetes mellitus; Insulin secretagogues; Ischemic heart disease; Mortality

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PHENFORMIN; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; INSULIN RELEASE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PRIORITY JOURNAL;

AGED; BIGUANIDES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RETROSPECTIVE STUDIES;

EID: 42649122987     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.03.135     Document Type: Article

References (15)

1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 9131 (1998) 854-865
2. Fisman E.Z., Tenenbaum A., Boyko V., et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 24 2 (2001) 151-158
3. Gulliford M., and Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 20 3 (2004) 239-245
4. Johnson J.A., Majumdar S.R., Simpson S.H., and Toth E.L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25 12 (2002) 2244-2248
5. Mannucci E., Monami M., Masotti G., and Marchionni N. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev 20 1 (2004) 44-47
6. Olsson J., Lindberg G., Gottsater M., et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43 5 (2000) 558-560
7. Evans J.M., Ogston S.A., Emslie-Smith A., and Morris A.D. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49 5 (2006) 930-936
8. Blackburn H. Classification of the electrocardiogram for population studies: Minnesota code. J Electrocardiol 2 (1969) 305-310 [Ref Type: Journal (Full)]
9. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 5 (1987) 373-383
10. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 8 (2006) 1963-1972
11. Johnsen S.P., Monster T.B., Olsen M.L., et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 13 2 (2006) 134-140
12. Monami M., Luzzi C., Lamanna C., et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 22 6 (2006) 477-482
13. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., and Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 330 7503 (2005) 1304-1305
14. Thisted H., Johnsen S.P., and Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism 55 5 Suppl 1 (2006) S16-S19
15. Scognamiglio R., Avogaro A., Vigili D., et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 51 3 (2002) 808-812